Gli studi sono progrediti dalle osservazioni iniziali in vitro fino a studi clinici controllati, in particolare nel campo dermatologico
Possible Protection for the Brain Ongoing Phase III trials are investigating whether GLP-1 agonists can reduce Alzheimers-related proteins and inflammation in the brain
First-time users or those with sensitive constitutions are recommended to start at 50 mg daily for 12 weeks to observe body tolerance
[1] Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score, Ghusn, Wissam et al., eClinicalMedicine, Volume 72, 102625 [2] [3] Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score, Ghusn, Wissam et al., eClinicalMedicine, Volume 72, 102625 [4] EP 2866825 [5] T 1701/22 Other News
co-create new product or service ideas with real users